Skip to main content

Advertisement

SpringerLink
Log in

Intravenous Migraine Treatment in Children and Adolescents

  • Childhood and Adolescent Headache (S Evers, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

A Correction to this article was published on 11 August 2020

This article has been updated

Abstract

Purpose of Review

Most treatment algorithms and guidelines for acute intravenous (IV) treatments of migraine for children and adolescents are derived from adult studies and often based on clinician’s personal experience regarding what is known to work. An overview of the current level of evidence of different acute IV treatments for migraine and status migrainosus in children and adolescents may help to improve provider’s approach and will emphasize the need for research in this field.

Recent Findings

Dihydroergotamine (DHE) is the most common therapy used in the inpatient setting especially those with intractable migraine lasting > 72 h (i.e., status migrainosus) not responding to usual oral or IV treatments. There may be some role of continuous infusion of valproic acid in the same group not responding to DHE or cannot tolerate DHE.

Summary

The purpose of this paper is to investigate clinical evidence of different modalities of IV treatments for children and adolescents with an intractable migraine attack and to discuss possible upcoming future treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Change history

  • 11 August 2020

    The original publication of this article unfortunately contained the incorrect version of the manuscript. The original article has been corrected.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Insinga RP, Ng-Mark DS, Hanson ME Costs associated with outpatient, emergency room and inpatient care for migraine in the USA. Cephalgia 2011; 31 (15) :1570–1575.

  2. Richer L, Graham L, Klassen T, Rowe B. Emergency department management of acute migraine in children in Canada: a practice variation study. Headache. 2007;47(5):703–10. https://doi.org/10.1111/j.1526-4610.2007.00782.x.

    Article  PubMed  Google Scholar 

  3. Richer LP, Laycock K, Millar K, Fitzpatrick E, Khangura S, Bhatt M, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126(1):e150–5. https://doi.org/10.1542/peds.2009-2337.

    Article  PubMed  Google Scholar 

  4. Nicholson R, Seng E, Smith T, Dummitt B, Yount B. Pediatric migraine treatment: poor adherence to evidence-based acute medication guidelines. 2015.

    Google Scholar 

  5. Kabbouche MA, Linder SL. Management of migraine in children and adolescents in the emergency department and inpatient setting. Curr Pain Headache Rep. 2005;9(5):363–7.

    Article  PubMed  Google Scholar 

  6. Bachur RG, Monuteaux MC, Neuman MI. A comparison of acute treatment regimens for migraine in the emergency department. Pediatrics. 2015;135:232–8.

    Article  PubMed  Google Scholar 

  7. Kabbouche MA, Vockell A-LB, LeCates SL, Powers SW, Hershey AD. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107:e62–2.

  8. Trottier ED, Bailey B, Dauphin-Pierre S, Gravel J. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010;39:166–73.

    Article  PubMed  Google Scholar 

  9. •• Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43:256–62 The only double-blind randomized trial for intravenous treatment of pediatric migraine.

  10. Kanis JM, Timm NL. Chlorpromazine for the treatment of migraine in a pediatric emergency department. Headache J Head Face Pain. 2014;54:335–42.

    Article  Google Scholar 

  11. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs during pregnancy and the initiation of lactation. Anesth Analg. 2013;116(5):1063–75. https://doi.org/10.1213/ANE.0b013e31828a4b54.

    Article  CAS  PubMed  Google Scholar 

  12. Karsan N, Prabhakar P, Goadsby PJ. Premonitory symptoms of migraine in childhood and adolescence. Curr Pain Headache Rep. 2017;21(7):34. https://doi.org/10.1007/s11916-017-0631-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. • Karsan N, Goadsby PJ. Biological insights from the premonitory symptoms of migraine. Nat Rev Neurol. 2018;14(12):699–710. https://doi.org/10.1038/s41582-018-0098-4Excellent review of the premonitory symptoms of migraine and why fluids are appropriate in the management.

  14. Richer L, Craig W, Rowe B. Randomized controlled trial of treatment expectation and intravenous fluid in pediatric migraine. Headache. 2014;54(9):1496–505. https://doi.org/10.1111/head.12443.

    Article  PubMed  Google Scholar 

  15. Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache. 1996;36(3):154–60.

    Article  CAS  PubMed  Google Scholar 

  16. Gertsch E, Loharuka S, Wolter-Warmerdam K, Tong S, Kempe A, Kedia S. Intravenous magnesium as acute treatment for headaches: a pediatric case series. J Emerg Med. 2014;46(2):308–12.

    Article  PubMed  Google Scholar 

  17. Krusz JC, Scott V, Belanger J. Intravenous propofol: unique effectiveness in treating intractable migraine. Headache. 2000;40(3):224–30. https://doi.org/10.1046/j.1526-4610.2000.00032.x.

    Article  CAS  PubMed  Google Scholar 

  18. Bloomstone JA. Propofol: a novel treatment for breaking migraine headache. Anesthesiology. 2007;106:405–6.

    Article  PubMed  Google Scholar 

  19. Soleimanpour H, Ghafouri RR, Taheraghdam A, et al. Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial. BMC Neurol. 2012;12:114.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Dhir A. Propofol in the treatment of refractory migraine headaches. Expert Rev Neurother. 2016;16:1007–11.

    Article  CAS  PubMed  Google Scholar 

  21. Robert S, Ghanayem H. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: propofol for migraine. Emerg Med J. 2013;30:688–9.

    PubMed  Google Scholar 

  22. Sheridan DC, Hansen ML, Lin AL, Fu R, Meckler GD. Low-dose propofol for pediatric migraine: a prospective, randomized controlled trial. J Emerg Med. 2018;54(5):600–6. https://doi.org/10.1016/j.jemermed.2018.01.003.

    Article  PubMed  Google Scholar 

  23. Sheridan DC, Spiro DM, Nguyen T, Koch TK, Meckler GD. Low-dose propofol for the abortive treatment of pediatric migraine in the emergency department. Pediatr Emerg Care. 2012;28(12):1293–6. https://doi.org/10.1097/PEC.0b013e3182768a6b.

    Article  PubMed  Google Scholar 

  24. • Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019;15(8):483–90. https://doi.org/10.1038/s41582-019-0216-yExcellent review about possible role of inflammation in migraine.

  25. Orr SL, Friedman BW, Christie S, Minen MT, Bamford C, Kelley NE, et al. Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache. 2016;56(6):911–40. https://doi.org/10.1111/head.12835.

    Article  PubMed  Google Scholar 

  26. Cobb-Pitstick KM, Hershey AD, O’Brien HL, Kabbouche MA, LeCates S, White S, et al. Factors influencing migraine recurrence after infusion and inpatient migraine treatment in children and adolescents. Headache. 2015;55(10):1397–403. https://doi.org/10.1111/head.12654.

    Article  PubMed  Google Scholar 

  27. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003;140(2):277–84. https://doi.org/10.1038/sj.bjp.0705437.PMC1574033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sara Frindinger, Christina Szperka. Effectiveness of intravenous dihydroergotamine for pediatric headache: does headache diagnosis matter? Neurology 2018: 90 (15 Supplement).

  29. Kabbouche M. Pediatric inpatient headache therapy: what is available. Headache. 2015;55(10):1426–9.

    Article  PubMed  Google Scholar 

  30. • Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49(1):106–9 Excellent evidence for the efficiency of intravenous dihydroergotamine in the treatment of status migraine.

  31. Eller M, Gelfand AA, Riggins NY, et al. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology. 2016;86(9):856–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Kacperski J, Kabbouche MA, O’Brien HL, Weberding JL. The optimal management of headaches in children and adolescents. Ther Adv Neurol Disord. 2016;9(1):53–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Linder SL. Treatment of childhood headache with dihydroergotamine mesylate. Headache J Head Face Pain. 1994;34:578–80.

    Article  CAS  Google Scholar 

  34. Nickisch J, Merritt G. The Department of Pharmacy, Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Denver, CO 80218, USA: The Children’s Hospital.

  35. Reiter PD. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45(7):899–903.

    Article  PubMed  Google Scholar 

  36. Cook Z, et al. Pharmacokinetics and clinical utility of valproic acid administered via continuous infusion. CNS Drugs. 2016;30(1):71–7. https://doi.org/10.1007/s40263-015-0304-5.

    Article  CAS  PubMed  Google Scholar 

  37. • Zafar, et al. Continuous intravenous valproate as abortive therapy for pediatric status migrainosus. Neurologist. 2018;23(2) Evidence for the efficiency of intravenous valproate in the treatment of status migraine.

  38. Berk T, Silberstein SD. The use and method of action of intravenous lidocaine and its metabolite in headache disorders. Headache. 2018;58(5):783–9. https://doi.org/10.1111/head.13298.

    Article  PubMed  Google Scholar 

  39. Ayulo MA Jr, Phillips KE, Tripathi S. Safety and efficacy of IV lidocaine in the treatment of children and adolescents with status migraine. Pediatr Crit Care Med. 2018;19(8):755–9. https://doi.org/10.1097/pcc.0000000000001629.

    Article  PubMed  Google Scholar 

  40. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–100. https://doi.org/10.1016/s1474-4422(15)00245-8.

    Article  CAS  PubMed  Google Scholar 

  41. Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–34. https://doi.org/10.1016/s1474-4422(17)30083-2.

    Article  CAS  PubMed  Google Scholar 

  42. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. https://doi.org/10.1056/NEJMoa1709038.

    Article  CAS  PubMed  Google Scholar 

  43. Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–54. https://doi.org/10.1177/0333102418779543.

    Article  PubMed  Google Scholar 

  44. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. Jama. 2018;319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853.

    Article  CAS  PubMed  Google Scholar 

  45. Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–8. https://doi.org/10.1001/jamaneurol.2018.1212.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075–85. https://doi.org/10.1177/0333102419858355.

    Article  PubMed  Google Scholar 

  47. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalgia. 2020;40(3):241–54.

    Article  Google Scholar 

  48. Kudrow D, Lipton R, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: results of 2 infusions in the phase 3 PROMISE-2 (Prevention of Migraine via Intravenous Eptinezumab Safety and Efficacy–2) Trial (P2.10 006). Neurology. 2019;92(15).

  49. • Nelson GR, Bale JF, Kerr LM. Outcome and cost of inpatient hospitalization for intravenous dihydroergotamine treatment of refractory pediatric headache. Pediatr Neurol. 2017;66:76–81. https://doi.org/10.1016/j.pediatrneurol.2016.09.009This reference highlights the importance of costs related to standard of care, i.e., DHE.

Download references

Author information

Author notes

  1. Sharoon Qaiser contributed equally to this work.

Authors and Affiliations

  1. Division of Pediatric Neurology, Duke University Medical Center, Durham, NC, USA

    Klaus Werner

  2. Department of Neurology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, E4-310, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA

    Sharoon Qaiser, Marielle Kabbouche & Andrew D. Hershey

  3. Medical Center Library & Archives, Duke University Medical Center, Durham, NC, 27710, USA

    Beverly Murphy

  4. Imperial College Healthcare NHS Trust, London, UK

    Ian Maconochie

Authors
  1. Klaus Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharoon Qaiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marielle Kabbouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Beverly Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ian Maconochie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew D. Hershey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Werner.

Ethics declarations

Conflict of Interest

Klaus Werner

No conflict of interest

Sharron Qaiser

No conflict of interest

Marielle Kabbouche

CGRP Ab

Alder/Lundbeck—site PI; payment to CCHMC

Lilly—site PI; payment to CCHMC

Topiramate

Supernus—site PI; payment to CCHMC

Beverly Murphy

No conflict of interest

Ian Maconochie

No conflict of interest

Andrew D. Hershey

CGRP Ab

Amgen—advisor to study, site PI; payment to CHMC

Alder/Lundbeck—advisor to study; payment to CCHMC

Lilly—advisor to both CGRP and Ditan studies; payment to CCHMC

Teva—advisor to study, not sure about site PI I am international PI for protocols; payment to CCHMC

CGRP antagonist

Allergan—advisor to study; payment to CCHMC

Biohaven—advisor to study; payment to CCHMC

Topiramate

UpsherSmith—advisor to study, site PI; mixed payment—some to CCHMC, some to me personally

Supernus—advisor to study; payment to CCHMC

Device

Electrocore—advisor to study, no payment

Theranica—advisor to study, I am both site PI and international PI; payment to CCHMC

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: The original publication contained the incorrect version of the manuscript.

This article is part of the Topical Collection on Childhood and Adolescent Headache

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Werner, K., Qaiser, S., Kabbouche, M. et al. Intravenous Migraine Treatment in Children and Adolescents. Curr Pain Headache Rep 24, 45 (2020). https://doi.org/10.1007/s11916-020-00867-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-020-00867-7

Keywords

Search

Navigation